EGFR and cancer: Molecular docking studies revealed that the newly designed compounds exhibited better binding affinities (−7.2 to −9.8 kcal/mol) to key cancer-related targets (CDK2, EGFR, and Tubulin) compared to the reference drug and the most active molecule (molecule 39) in the dataset.